Major Depressive Disorder

What Healing TMS Clinic offers for major depressive disorder: rTMS therapy (Brain Ultimate M Series or Sabers Blossom for standard protocols; BrainsWay Deep TMS for select indications) and psychiatric medication management. Spravato (esketamine) and structured psychotherapy are not currently offered in-house; patients seeking those modalities are referred to other providers.

Major depressive disorder (MDD) is a mood disorder characterized by at least one major depressive episode lasting two weeks or longer, with persistent depressed mood or anhedonia accompanied by neurovegetative, cognitive, and somatic disturbance.¹ It is distinct from situational sadness, grief, or transient low mood — MDD reflects sustained dysregulation of cortico-limbic circuits and monoaminergic neurotransmission. Lifetime prevalence in U.S. adults is approximately 20.6%, with twelve-month prevalence near 10.4%.² MDD is a leading cause of disability worldwide and is diagnosed by clinical interview against the diagnostic criteria codified in the DSM-5-TR, not by symptom checklist alone.¹

Recognized signs and symptoms

Affective

• Depressed mood most of the day, nearly every day
• Markedly diminished interest or pleasure (anhedonia) in nearly all activities
• Feelings of worthlessness or excessive, inappropriate guilt

Neurovegetative

• Significant change in appetite or weight (≥5% in a month)
• Insomnia or hypersomnia nearly every day
• Psychomotor agitation or retardation observable by others
• Fatigue or loss of energy

Cognitive

• Diminished ability to concentrate, indecisiveness
• Recurrent thoughts of death, suicidal ideation, or a suicide plan or attempt

Diagnostic criteria

The DSM-5-TR requires five or more of the symptoms above present during the same two-week period, with at least one being depressed mood or anhedonia, causing clinically significant distress or impairment, and not attributable to a substance, medical condition, or another psychiatric disorder.¹ Diagnosis is established by a qualified clinician through structured interview; validated severity instruments such as the PHQ-9 and the Hamilton Depression Rating Scale (HDRS) support assessment and treatment tracking but do not replace diagnostic evaluation. This page is educational and is not a tool for self-diagnosis.

Treatment options at Healing TMS Clinic

First-line interventions for MDD follow APA and CANMAT guidelines and typically include a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) paired with evidence-based psychotherapy. Approximately 50–60% of patients do not achieve full remission with the first antidepressant trial, and roughly one-third remain symptomatic after multiple sequential trials.³ Treatment paths we coordinate include:

• Medication management — SSRIs, SNRIs, bupropion, mirtazapine, and adjunctive agents (atypical antipsychotics, lithium, thyroid augmentation) selected against side-effect profile and prior response.
• Evidence-based psychotherapy — cognitive behavioral therapy (CBT), behavioral activation, and interpersonal therapy (IPT), referred to vetted clinicians within our network.
• TMS Therapy — FDA-cleared repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex, indicated for MDD in adults who have not responded to antidepressant medication.⁴ Real-world registry data report response rates of approximately 58% and remission rates near 37%.⁵

When to consider TMS Therapy

TMS is an appropriate consideration for MDD when a patient has had an inadequate response to at least one antidepressant trial at adequate dose and duration during the current episode, and is increasingly indicated after two or more failures.⁴ Candidates are typically adults without a history of seizure disorder, without ferromagnetic implants in or near the head, and not pregnant (pregnancy is a relative contraindication evaluated case-by-case). TMS is non-systemic, requires no anesthesia, and has a favorable side-effect profile compared with adjunctive pharmacotherapy. The standard course is 36 sessions over 6–9 weeks; full clinical evaluation determines candidacy. See our TMS Therapy page for mechanism, protocol, and safety detail.

Insurance and TMS for depression

Most major commercial carriers and Medicare cover TMS therapy for MDD when the patient meets payer-specific criteria — typically documentation of at least two failed antidepressant trials at adequate dose and duration, an adequate trial of psychotherapy where required, and a current PHQ-9 or HDRS score consistent with moderate-to-severe illness. Prior authorization is standard and timelines vary by carrier from several days to several weeks.

Our team handles benefits verification and prior-authorization paperwork on your behalf. Submit your insurance information through our verification form and we will confirm your TMS coverage, expected copay, and any documentation needed before treatment begins.

What to expect at your consultation

Your initial consultation is a clinical evaluation with a psychiatrist serving Anaheim, Orange County, and the surrounding 30-mile radius. Expect a structured diagnostic interview, review of medication and treatment history, severity measurement, and a discussion of options — including whether TMS is clinically appropriate. Schedule a consultation to begin.

References